Report
Kelsey Tsai

Syneos is well-positioned to benefit from long-term industry growth.

Following solid fourth-quarter results, shares of Syneos, formerly INC Research/inVentiv Health, saw marked recovery, but still remain undervalued relative to our current $53 per share fair value estimate. We plan on raising our fair value estimate slightly to reflect our more optimistic 2018 sales forecasts and accelerated cost synergies from the merger. Earlier this month, shares tumbled 18% after the announcement of the accelerated departure of former CFO Greg Rush and general counsel Christo...
Underlying
Syneos Health Inc. Class A

Syneos Health is a holding company. Through its subsidiaries, the company is a biopharmaceutical solutions organization providing a suite of clinical and commercial services to customers in the biopharmaceutical, biotechnology, and medical device industries. The company has two reportable segments: Clinical Solutions, which provides a variety of clinical development services spanning Phase I to Phase IV, including global studies, unbundled service offerings, and Real World Evidence studies; and Commercial Solutions, which provides customers with a range of commercialization services, including field teams and medication adherence services, communications solutions, and consulting services.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Kelsey Tsai

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch